SELLAS narrows losses as cash position strengthens to $114M
Biotech reports 50% reduction in FY2025 net loss while Phase 3 REGAL trial approaches final analysis with 72 of 80 events recorded
SELLAS Life Sciences reported a 50% year-over-year reduction in its net loss for fiscal year 2025, narrowing the deficit to $26.9 million from $30.9 million, as the biotechnology company tightened operational expenses while advancing its cancer immunotherapy pipeline through critical clinical milestones.
The New York-based company posted earnings per share of negative 25 cents, missing analyst expectations of negative 8 cents, according to regulatory filings submitted Thursday. For pre-revenue biotechnology companies, however, EPS misses are common as firms prioritize research and development over profitability, with investors focusing instead on cash management and clinical trial progress.
SELLAS demonstrated significant financial discipline during the period, reducing research and development spending to $16.0 million from $19.1 million in the prior year. The company's cash position strengthened considerably to $114.4 million, comprising $71.8 million on the balance sheet and an additional $42.6 million from warrant exercises completed in the first quarter of 2026.
The strengthened balance sheet provides a substantial runway as SELLAS approaches several near-term clinical catalysts that could determine the company's trajectory. Shares, which closed Thursday at $5.20, are up more than 5% and have more than quintupled from their 52-week low of 95 cents reached in August 2025. The stock remains below its 52-week high of $6.14.
The most significant upcoming catalyst involves the Phase 3 REGAL trial evaluating galinpepimut-S, the company's lead cancer immunotherapy candidate, in acute myeloid leukemia. The trial has now recorded 72 of 80 required events, with final analysis expected upon reaching the 80-event milestone. Acute myeloid leukemia is an aggressive blood cancer with limited treatment options, creating a substantial market opportunity if the therapy demonstrates efficacy.
"We are pleased with the continued progress of our pivotal Phase 3 REGAL trial of GPS in AML, which now has 72 of the 80 events required for the final analysis," the company stated in its earnings announcement. "We look forward to completing the trial and reporting top-line results in the second quarter of 2026."
In addition to the REGAL trial, SELLAS announced that the first patient has been dosed in an expansion cohort evaluating SLS009 for first-line treatment of acute myeloid leukemia. SLS009, a small molecule inhibitor of CDK9, represents a second key asset in the company's oncology pipeline, diversifying its therapeutic approach beyond peptide-based immunotherapies.
Analyst sentiment remains cautiously optimistic on SELLAS, with three analysts covering the stock collectively rating it as either strong buy or buy, according to market data. The consensus price target stands at $7.83, representing roughly 50% upside from current levels. Institutional investors hold approximately 19.8% of outstanding shares, while insider ownership remains low at 0.6%. With a market capitalization of roughly $858 million and 170 million shares outstanding, the company trades at approximately 20 times book value.
The company's focus on immunotherapy approaches reflects broader industry trends, as cancer treatments increasingly harness the immune system to target malignancies. Peptide-based vaccines like galinpepimut-S aim to stimulate T-cell responses against tumor-specific antigens, potentially offering lower toxicity profiles compared to traditional chemotherapy.
For investors, the next two quarters will prove critical. The REGAL trial data readout, expected in Q2 2026, represents a binary event that could significantly impact the company's valuation. Positive results could validate SELLAS's approach and potentially support regulatory submissions, while negative data would likely force the company to reassess its strategy and potentially explore strategic alternatives.
The $114.4 million cash position should provide sufficient funding to reach these key catalysts, though the rate of cash burn will require ongoing monitoring. With the REGAL trial approaching its final analysis milestone, SELLAS enters what may prove to be the most consequential period in its corporate history.